PCN220 COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

Autor:	R. Leme-Souza, Maiara Rodrigues dos Santos, S.D. Stefani, D. Kashiura, L. Fahham
Rok vydání:	2019
Předmět:	Alectinib Oncology medicine.medical_specialty Crizotinib business.industry Health Policy Perspective (graphical) Public Health Environmental and Occupational Health ALK-Positive Cost-effectiveness analysis medicine.disease Internal medicine medicine Private healthcare Non small cell Lung cancer business medicine.drug
Zdroj:	Value in Health. 22:S478-S479
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.416
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ecaa19a4504b6debfee509d8e19b3019 https://doi.org/10.1016/j.jval.2019.09.416 Zobrazit plný text záznamu Full Text from ScienceDirect